These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21130138)

  • 1. Biomarkers for Alzheimer's disease therapeutic trials.
    Hampel H; Wilcock G; Andrieu S; Aisen P; Blennow K; Broich K; Carrillo M; Fox NC; Frisoni GB; Isaac M; Lovestone S; Nordberg A; Prvulovic D; Sampaio C; Scheltens P; Weiner M; Winblad B; Coley N; Vellas B;
    Prog Neurobiol; 2011 Dec; 95(4):579-93. PubMed ID: 21130138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
    Hampel H; Shen Y; Walsh DM; Aisen P; Shaw LM; Zetterberg H; Trojanowski JQ; Blennow K
    Exp Neurol; 2010 Jun; 223(2):334-46. PubMed ID: 19815015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.
    Lista S; Dubois B; Hampel H
    J Nutr Health Aging; 2015 Feb; 19(2):154-63. PubMed ID: 25651440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
    Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
    PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological markers for early detection and pharmacological treatment of Alzheimer's disease.
    Hampel H; Broich K; Hoessler Y; Pantel J
    Dialogues Clin Neurosci; 2009; 11(2):141-57. PubMed ID: 19585950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
    Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
    J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of neuroimaging to disease-modification trials in Alzheimer's disease.
    Fleisher AS; Donohue M; Chen K; Brewer JB; Aisen PS;
    Behav Neurol; 2009; 21(1):129-36. PubMed ID: 19847051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.
    Dickerson BC; Sperling RA
    NeuroRx; 2005 Apr; 2(2):348-60. PubMed ID: 15897955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
    Lista S; Molinuevo JL; Cavedo E; Rami L; Amouyel P; Teipel SJ; Garaci F; Toschi N; Habert MO; Blennow K; Zetterberg H; O'Bryant SE; Johnson L; Galluzzi S; Bokde AL; Broich K; Herholz K; Bakardjian H; Dubois B; Jessen F; Carrillo MC; Aisen PS; Hampel H
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S171-91. PubMed ID: 26402088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates.
    Hroudová J; Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Aug; 134():111069. PubMed ID: 38917881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.
    Khan TK; Alkon DL
    J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.